Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
OncoSec to expand KEYNOTE-890 study with combination with TAVO and KEYTRUDA » 09:06
06/09/20
06/09
09:06
06/09/20
09:06
ONCS

OncoSec

$2.22 /

+0.01 (+0.45%)

, MRK

Merck

$82.93 /

+0.67 (+0.81%)

OncoSec Medical (ONCS)…

OncoSec Medical (ONCS) announced that, based upon tumor regression and associated clinical responses observed in the heavily pretreated Cohort 1 of the KEYNOTE-890 study, the Company plans to expand into earlier first-line treatment to investigate the combination of OncoSec's lead product candidate TAVO, or plasmid-based interleukin-12 or pIL-12, and Merck's (MRK) KEYTRUDA, or pembrolizumab, plus chemotherapy in patients with inoperable locally advanced or metastatic triple negative breast cancer, or mTNBC. Cohort 2 will be added as a second arm to the ongoing KEYNOTE-890 study. Merck's Phase 3 KEYNOTE-355 trial evaluating KEYTRUDA in combination with chemotherapy in first-line mTNBC recently reported a statistically significant and clinically meaningful improvement in progression free survival with the combination of KEYTRUDA plus chemotherapy versus chemotherapy alone for first-line treatment of patients with PD-L1 positive mTNBC. Safety was consistent with known profiles of each regimen. These findings, as well as the strong signal, even in patients with PD-L1 negative tumors, and excellent safety profile observed in KEYNOTE-890 Cohort 1, served as the basis for OncoSec's decision to move into first-line mTNBC.

ShowHide Related Items >><<
ONCS OncoSec
$2.22 /

+0.01 (+0.45%)

MRK Merck
$82.93 /

+0.67 (+0.81%)

ONCS OncoSec
$2.22 /

+0.01 (+0.45%)

12/16/19 Piper Sandler
OncoSec price target lowered to $7 from $8 at Piper Jaffray
10/10/19 Piper Sandler
Piper keeps Overweight on OncoSec after China Grand investment
MRK Merck
$82.93 /

+0.67 (+0.81%)

06/04/20 BMO Capital
NGM Biopharmaceuticals initiated with an Outperform at BMO Capital
06/03/20 Alliance Global Partners
OpGen, NYS DOH collaboration extension 'highly positive,' says Alliance Global
06/02/20 JPMorgan
JPMorgan positions for second half with three picks in Major Pharma
05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
MRK Merck
$82.93 /

+0.67 (+0.81%)

MRK Merck
$82.93 /

+0.67 (+0.81%)

MRK Merck
$82.93 /

+0.67 (+0.81%)

MRK Merck
$82.93 /

+0.67 (+0.81%)

Over a month ago
Hot Stocks
OncoSec announces Notices of Allowance for three new patent applications » 09:02
05/27/20
05/27
09:02
05/27/20
09:02
ONCS

OncoSec

$2.47 /

+0.08 (+3.35%)

OncoSec Medical announced…

OncoSec Medical announced Notices of Allowance for three new patent applications covering its interleukin-12 based immunotherapy platform, including its lead product candidate TAVO and next-generation product candidate TAVOPLUS, and electroporation gene delivery system.

ShowHide Related Items >><<
ONCS OncoSec
$2.47 /

+0.08 (+3.35%)

ONCS OncoSec
$2.47 /

+0.08 (+3.35%)

12/16/19 Piper Sandler
OncoSec price target lowered to $7 from $8 at Piper Jaffray
10/10/19 Piper Sandler
Piper keeps Overweight on OncoSec after China Grand investment
Hot Stocks
OncoSec's Tavo granted ATMP certification in Europe for application in melanoma » 09:22
05/13/20
05/13
09:22
05/13/20
09:22
ONCS

OncoSec

$1.68 /

+0.06 (+3.70%)

OncoSec announced the…

OncoSec announced the European Medicines Agency issued an advanced therapy medicinal product, or ATMP, certificate for chemistry manufacturing controls data covering its lead product candidate, Tavo, for the treatment of metastatic melanoma. Following Tavo's classification as an ATMP last year, the certification procedure involved a thorough scientific evaluation over several months of CMC data for TAVO by the EMA's Committee for Advanced Therapies. After a positive opinion from CAT, EMA issued a certificate confirming that the CMC data comply with the standards that apply for evaluating the Marketing Authorization Application. The Committee for Advanced Therapies is the committee at the European Medicines Agency that is responsible for classifying and assessing the quality, safety and efficacy of advanced-therapy medicinal products and following scientific developments in the field. The ATMP designation is a classification for certain medicines for human use that are gene-, cell-, or tissue-based. The main responsibility of the CAT is to prepare a draft opinion on each ATMP application submitted to the European Medicines Agency, before the Committee for Medicinal Products for Human Use adopts a final opinion on granting a marketing authorization for the product. OncoSec has expanded its pivotal KEYNOTE-695 study of Tavo to Europe, laying the foundation for a MAA submission within the EU.

ShowHide Related Items >><<
ONCS OncoSec
$1.68 /

+0.06 (+3.70%)

ONCS OncoSec
$1.68 /

+0.06 (+3.70%)

12/16/19 Piper Sandler
OncoSec price target lowered to $7 from $8 at Piper Jaffray
10/10/19 Piper Sandler
Piper keeps Overweight on OncoSec after China Grand investment
05/22/19
OncoSec interim Phase II data 'compelling,' says Piper Jaffray
Hot Stocks
OncoSec's Tavo combined with Keytruda achieves 41% Overall Response Rates » 09:08
05/06/20
05/06
09:08
05/06/20
09:08
ONCS

OncoSec

$1.70 /

+0.01 (+0.59%)

Oncosec announced…

Oncosec announced published data in Clinical Cancer Research that demonstrated its lead product candidate, Tavo, in combination with the anti-PD-1 checkpoint inhibitor Keytruda, produced a 41% overall response rate or ORR, with 36% complete response in a Phase 2, single arm study evaluating patients with metastatic melanoma selected to be anti-PD-1 checkpoint resistant. In the trial, responses were observed in nine of 22 evaluable patients, for an objective response rate of 41%. 36% of patients experienced a complete response. Median progression-free survival was 5.6 months, with median overall survival not yet reached after a median follow-up of 19.6 months. Grade 3 or higher adverse events were limited and included pain, chills, sweat and cellulitis. The KEYNOTE-695 study is a pivotal, global, open-label trial of Tavo in combination with Keytruda in patients with anti-PD-1 checkpoint resistant metastatic melanoma. Tavo has been designated fast track and orphan drug status by the FDA and following completion of the KEYNOTE-695 study OncoSec intends to file for accelerated U.S. approval.

ShowHide Related Items >><<
ONCS OncoSec
$1.70 /

+0.01 (+0.59%)

12/16/19 Piper Sandler
OncoSec price target lowered to $7 from $8 at Piper Jaffray
10/10/19 Piper Sandler
Piper keeps Overweight on OncoSec after China Grand investment
05/22/19
OncoSec interim Phase II data 'compelling,' says Piper Jaffray
Hot Stocks
OncoSec announces pre-clinical data from study of its VLA device » 09:04
04/21/20
04/21
09:04
04/21/20
09:04
ONCS

OncoSec

$1.55 /

-0.01 (-0.64%)

OncoSec Medical announced…

OncoSec Medical announced pre-clinical data from a feasibility study of its visceral lesion applicator, or VLA, electroporation device and APOLLO generator which were presented online at the Annual Meeting of the Society of Interventional Radiology, or SIR. The feasibility study demonstrated the capability of a rigid, trocar-like VLA applicator to safely deliver and electroporate DNA-based immunotherapy directly into target organs in a large animal model using a CT-guided approach and OncoSec's new, lower voltage APOLLO generator. In the study presented online at the Annual Meeting of the SIR, OncoSec demonstrated the ability to guide and deploy the VLA under a different guidance method and electroporate with the APOLLO generator.

ShowHide Related Items >><<
ONCS OncoSec
$1.55 /

-0.01 (-0.64%)

12/16/19 Piper Sandler
OncoSec price target lowered to $7 from $8 at Piper Jaffray
10/10/19 Piper Sandler
Piper keeps Overweight on OncoSec after China Grand investment
05/22/19
OncoSec interim Phase II data 'compelling,' says Piper Jaffray
Hot Stocks
OncoSec collaborates with PCI on investigational COVID-19 vaccine » 09:09
04/06/20
04/06
09:09
04/06/20
09:09
ONCS

OncoSec

$2.04 /

-0.16 (-7.27%)

OncoSec announced that…

OncoSec announced that Providence Cancer Institute, a part of Providence St. Joseph Health, is pursuing a first-in-human Phase 1 clinical trial of OncoSec's novel DNA-encodable, investigational vaccine, CORVax12, which is designed to act as a prophylactic vaccine to prevent COVID-19. CORVax12 consists of OncoSec's existing product candidate, TAVO, in combination with an immunogenic component of the SARS-CoV-2 virus recently developed by researchers at NIH's National Institute of Allergy and Infectious Diseases and licensed to OncoSec on a non-exclusive basis. OncoSec will supply CORVax12 and its investigational APOLLO electroporation device to Providence as part of this effort and does not anticipate any additional capital commitment at this time. Additionally, OncoSec will contribute manufacturing, preclinical, and prior clinical information and data for TAVO, along with manufacturing data for its APOLLO technology, to support FDA's allowance of the Providence IND. Providence will hold the IND, if cleared by FDA, and perform the preclinical and clinical development work.

ShowHide Related Items >><<
ONCS OncoSec
$2.04 /

-0.16 (-7.27%)

12/16/19 Piper Sandler
OncoSec price target lowered to $7 from $8 at Piper Jaffray
10/10/19 Piper Sandler
Piper keeps Overweight on OncoSec after China Grand investment
05/22/19
OncoSec interim Phase II data 'compelling,' says Piper Jaffray
Over a quarter ago
Hot Stocks
OncoSec jumps as traders circulate CORVax12 vaccine fact sheet » 11:08
04/02/20
04/02
11:08
04/02/20
11:08
ONCS

OncoSec

$1.88 /

+0.23 (+13.94%)

Shares of OncoSec have…

Shares of OncoSec have jumped 36c, or 22%, to $2.03 in early trading as traders circulate a fact sheet on the company's CORVax12 vaccine, according to contacts. CORVax12 is described in the fact sheet as "a novel DNA-encodable vaccine delivered by reversible electroporation, is designed to prevent SARS-CoV-2 infection and address the COVID-19 pandemic." Reference Link

ShowHide Related Items >><<
ONCS OncoSec
$1.88 /

+0.23 (+13.94%)

12/16/19 Piper Sandler
OncoSec price target lowered to $7 from $8 at Piper Jaffray
10/10/19 Piper Sandler
Piper keeps Overweight on OncoSec after China Grand investment
05/22/19
OncoSec interim Phase II data 'compelling,' says Piper Jaffray
Hot Stocks
OncoSec announces publication of TAVO monotherapy data » 08:32
03/17/20
03/17
08:32
03/17/20
08:32
ONCS

OncoSec

$1.24 /

-0.07 (-5.34%)

OncoSec Medical announced…

OncoSec Medical announced the publication of positive TAVO monotherapy data in patients with metastatic melanoma in the Annals of Oncology. The publication titled, "Intratumoral Delivery of Tavokinogene Telseplasmid Yields Systemic Immune Responses in Metastatic Melanoma Patients," features data previously highlighted at both American Association of Cancer Research, or AACR, and the Melanoma Bridge annual meetings. Annals of Oncology is the official publication of the European Society for Medical Oncology. The publication describes OncoSec's study of patients with Stage III/IV melanoma who were treated intratumorally with plasmid encoding IL-12, followed by electroporation on days 1, 5, and 8 every 90 days in the main study with additional patients treated in two exploration cohorts with alternative schedules. The publication concluded that intratumoral TAVO was well-tolerated and led to systemic immune responses in advanced melanoma patients. While tumor regression and increased immune infiltration were observed in treated as well as untreated/distal lesions, adaptive immune resistance limited the response.

ShowHide Related Items >><<
ONCS OncoSec
$1.24 /

-0.07 (-5.34%)

12/16/19 Piper Sandler
OncoSec price target lowered to $7 from $8 at Piper Jaffray
10/10/19 Piper Sandler
Piper keeps Overweight on OncoSec after China Grand investment
05/22/19
OncoSec interim Phase II data 'compelling,' says Piper Jaffray
Hot Stocks
OncoSec receives $850,000 from Australian R&D Tax Incentive program » 08:34
03/11/20
03/11
08:34
03/11/20
08:34
ONCS

OncoSec

$1.52 /

-0.04 (-2.56%)

OncoSec Medical announced…

OncoSec Medical announced that it has received a Research and Development Tax Incentive cash rebate of $850,000 from the Australian Tax Office. The Australian government established this tax incentive program to stimulate local industry investment in R&D by offering businesses tax offsets for eligible R&D expenditures made in Australia. OncoSec previously established a subsidiary in Australia and is conducting a portion of both of its TAVO KEYNOTE clinical trials as well as other R&D activities in the region. This work enables OncoSec to qualify for the program and obtain reimbursement for certain expenditures.

ShowHide Related Items >><<
ONCS OncoSec
$1.52 /

-0.04 (-2.56%)

12/16/19 Piper Sandler
OncoSec price target lowered to $7 from $8 at Piper Jaffray
10/10/19 Piper Sandler
Piper keeps Overweight on OncoSec after China Grand investment
05/22/19
OncoSec interim Phase II data 'compelling,' says Piper Jaffray
Hot Stocks
OncoSec says class action litigation brought by Alpha Holdings dismissed » 08:34
03/09/20
03/09
08:34
03/09/20
08:34
ONCS

OncoSec

$1.60 /

+0.08 (+5.26%)

OncoSec announced that…

OncoSec announced that the class action and related books and records litigation brought by Alpha Holdings in Nevada state court have been dismissed, with prejudice. The class action sought to enjoin the closing of a strategic investment and relationship that OncoSec secured from two partners, Grand Decade Developments Limited, and its U.S. affiliate, Sirtex Medical US Holdings. The class action was commenced in late 2019 by Alpha, a South Korea-based institutional investor in OncoSec. On March 5, the Eighth Judicial District Court in Clark County Nevada dismissed all of Alpha's claims against OncoSec, with prejudice. Since Alpha's cases were dismissed with prejudice, they cannot be relitigated and OncoSec has no liability to Alpha.

ShowHide Related Items >><<
ONCS OncoSec
$1.60 /

+0.08 (+5.26%)

12/16/19 Piper Sandler
OncoSec price target lowered to $7 from $8 at Piper Jaffray
10/10/19 Piper Sandler
Piper keeps Overweight on OncoSec after China Grand investment
05/22/19
OncoSec interim Phase II data 'compelling,' says Piper Jaffray

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.